Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LUMOS PHARMA, INC.

(LUMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Lumas Pharma Shares Drop 12% After Treatment Period Extended

07/21/2021 | 12:37pm EDT

By Chris Wack

Lumos Pharma Inc. shares were down 12% to $8.29 after the company said primary six-month data for its phase 2 OraGrowtH210 trial is expected in the second half of 2023.

With the new timeline, the biopharmaceutical company said the treatment period will be extended to 12 months.

The company said the pace of site initiation and enrollment of the trial has been slower than anticipated primarily due to Covid-19 restrictions. That impact has been particularly pronounced at international sites where faster patient enrollment was anticipated. The trial's primary outcome continues to be the preliminary validation of its predictive enrichment markers strategy.

Lumos said the Food and Drug Administration has now requested an extension of the Trial to 12 months. The planned protocol extension mirrors the first six months of the OraGrowtH211 long-term extension study. The FDA has placed the planned long-term extension study on partial clinical hold until additional efficacy data from the trial are available to be reviewed.

Wainwright & Co. lowered its price target on Lumos Pharma to $27 from $34 a share, while keeping a Buy rating on the shares.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

07-21-21 1236ET

All news about LUMOS PHARMA, INC.
08:01aLUMOS PHARMA : Announces the Promotion of COO and Chief Scientific Officer, John..
AQ
07/26Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Resea..
GL
07/26Lumos Pharma, Inc. Appoints Mark Bach to the Company’s Clinical Scientific Ad..
CI
07/22LUMOS PHARMA : Roth Capital Adjusts Lumos Pharma's Price Target to $35 From $51,..
MT
07/22LUMOS PHARMA : to Report Second Quarter 2021 Financial Results and Host Conferen..
AQ
07/21SECTOR UPDATE : Health Care Stocks Mixed Ahead of Wednesday Close
MT
07/21LUMOS PHARMA : Drops After Reporting Slower-Than-Expected Enrollment for Pediatr..
MT
07/21Lumas Pharma Shares Drop 12% After Treatment Period Extended
DJ
07/21LUMOS PHARMA : HC Wainwright Adjusts Price Target on Lumos Pharma to $27 From $3..
MT
07/21LUMOS PHARMA : Announces Clinical Updates (Form 8-K)
PU
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -36,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,80x
Yield 2021 -
Capitalization 63,4 M 63,4 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 28
Free-Float 75,1%
Chart LUMOS PHARMA, INC.
Duration : Period :
Lumos Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LUMOS PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 7,60 $
Average target price 26,83 $
Spread / Average Target 253%
EPS Revisions
Managers and Directors
Richard J. Hawkins Chairman, President & Chief Executive Officer
Lori Lawley Chief Financial & Accounting Officer
John C. McKew Chief Operating & Scientific Officer
Thomas A. Raffin Independent Director
Kevin M. Lalande Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LUMOS PHARMA, INC.-78.72%63
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 907